Beta-adrenergic blocker mortality trials in congestive heart failure

American Journal of Cardiology

Volumn 84, Issue 9 SUPPL. 1, 1999, Pages 94-102

  Teerlink, John R ^a   Massie, Barry M ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; METOPROLOL; PLACEBO;

CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DISEASE COURSE; DISEASE SEVERITY; HUMAN; MORTALITY; PRIORITY JOURNAL; SUDDEN DEATH; SURVIVAL;

ADRENERGIC BETA-ANTAGONISTS; DEATH, SUDDEN, CARDIAC; HEART FAILURE, CONGESTIVE; HUMANS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0032703767     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00709-2     Document Type: Conference Paper

References (42)

1. Eichhorn E.J., Hjalmarson A. Beta-blocker treatment for chronic heart failure. The frog prince. Circulation. 90:1994;2153-2156.
2. Joseph J., Gilbert E.M. The sympathetic nervous system in chronic heart failure. Prog Cardiovasc Dis. 48:1998;9-16.
3. Eichhorn E.J., Bristow M.R. Medical therapy can improve the biological properties of the chronically failing heart a new era in the treatment of heart failure . Circulation. 94:1996;2285-2296.
4. Bristow M., Port J.D. Beta-adrenergic blockade in chronic heart failure. Scand Cardiovasc J Suppl. 47:1998;45-55.
5. Kern M.J. Appreciating alpha-adrenergic receptors and their role in ischemic left ventricular dysfunction [editorial comment]. Circulation. 99:1999;468-471.
6. Waagstein F., Hjalmarson A., Varnauskas E., Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 37:1975;1022-1036.
7. Swedberg K., Hjalmarson A., Waagstein F., Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet. 1:1979;1374-1376.
8. Swedberg K., Hjalmarson A., Waagstein F., Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J. 44:1980;117-133.
9. Swedberg K., Hjalmarson A., Waagstein F., Wallentin I. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J. 44:1980;134-142.
10. Waagstein F., Caidahl K., Wallentin I., Bergh C.H., Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol . Circulation. 80:1989;551-563.
11. Ikram H., Fitzpatrick D. Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet. 2:1981;490-493.
12. Ikram H., Chan W., Bennett S.I., Bones P.J. Haemodynamic effects of acute beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 42:1979;311-315.
13. Currie P.J., Kelly M.J., McKenzie A., Harper R.W., Lim Y.L., Federman J., Anderson S.T., Pitt A. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol. 3:1984;203-209.
14. Engelmeier R.S., O'Connell J.B., Walsh R., Rad N., Scanlon P.J., Gunnar R.M. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy a double-blind, randomized, placebo-controlled trial . Circulation. 72:1985;536-546.
15. Anderson J.L., Lutz J.R., Gilbert E.M., Sorensen S.G., Yanowitz F.G., Menlove R.L., Bartholomew M. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 55:1985;471-475.
16. Waagstein F., Bristow M.R., Swedberg K., Camerini F., Fowler M.B., Silver M.A., Gilbert E.M., Johnson M.R., Goss F.G., Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 342:1993;1441-1446.
17. 3-year follow-up of patients randomised in the metoprolol in dilated cardiomyopathy trial. Lancet. 351:1998;1180-1181.
18. Teerlink J.R., Goldhaber S.Z., Pfeffer M.A. An overview of contemporary etiologies of congestive heart failure. Am Heart J. 121:1991;1852-1853.
19. Massie B.M., Shah N.B. Evolving trends in the epidemiologic factors of heart failure rationale for preventive strategies and comprehensive disease management . Am Heart J. 133:1997;703-712.
20. Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). Am J Cardiol. 80:(suppl):1997;54J-58J.
21. Effect of metoprolol CR/XL in chronic heart failure Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) . Lancet. 353:1999;2001-2007.
22. A randomized trial of beta-blockade in heart failure The Cardiac Insufficiency Bisoprolol Study (CIBIS) . Circulation. 90:1994;1765-1773.
23. Design of the cardiac insufficiency bisoprolol study II (CIBIS II). Fundam Clin Pharmacol. 11:1997;138-142.
24. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) a randomised trial . Lancet. 353:1999;9-13.
25. Packer M., Colucci W.S., Sackner-Bernstein J.D., Liang C.S., Goldscher D.A., Freeman I., Kukin M.L., Kinhal V., Udelson J.E., Klapholz M., Gottlieb S.S., Pearle D., Cody R.J., Gregory J.J., Kantrowitz N.E., LeJemtel T.H., Young S.T., Lukas M.A., Shusterman N.H. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation. 94:1996;2793-2799.
26. Colucci W.S., Packer M., Bristow M.R., Gilbert E.M., Cohn J.N., Fowler M.B., Krueger S.K., Hershberger R., Uretsky B.F., Bowers J.A., Sackner-Bernstein J.D., Young S.T., Holcslaw T.L., Lukas M.A. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 94:1996;2800-2806.
27. Bristow M.R., Gilbert E.M., Abraham W.T., Adams K.F., Fowler M.B., Hershberger R.E., Kubo S.H., Narahara K.A., Ingersoll H., Krueger S., Young S., Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 94:1996;2807-2816.
28. Cohn J.N., Fowler M.B., Bristow M.R., Colucci W.S., Gilbert E.M., Kinhal V., Krueger S.K., Lejemtel T., Narahara K.A., Packer M., Young S.T., Holcslaw T.L., Lukas M.A. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. J Card Fail. 3:1997;173-179.
29. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 334:1996;1349-1355.
30. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 349:1997;375-380.
31. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation. 92:1995;212-218.
32. Fisher L.D., Moyé L.A. Carvedilol and the Food and Drug Administration approval process an introduction . Control Clin Trials. 20:1999;1-15.
33. Moyé LA. End-point interpretation in clinical trials: the case for discipline. Control Clin Trials 1999;20:40-49;50-51.
34. Fisher L.D. Carvedilol and the Food and Drug Administration (FDA) approval process the FDA paradigm and reflections on hypothesis testing . Control Clin Trials. 20:1999;16-39.
35. Gilbert E.M., Anderson J.L., Deitchman D., Yanowitz F.G., O'Connell J.B., Renlund D.G., Bartholomew M., Mealey P.C., Larrabee P., Bristow M.R. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy a double-blind, randomized study of bucindolol versus placebo . Am J Med. 88:1990;223-229.
36. Bristow M.R., O'Connell J.B., Gilbert E.M., French W.J., Leatherman G., Kantrowitz N.E., Orie J., Smucker M.L., Marshall G., Kelly P., et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation. 89:1994;1632-1642.
37. Design of the Beta-Blocker Evaluation Survival Trial (BEST). Am J Cardiol. 75:1995;1220-1223.
38. Heidenreich P.A., Lee T.T., Massie B.M. Effect of beta-blockade on mortality in patients with heart failure a meta-analysis of randomized clinical trials . J Am Coll Cardiol. 30:1997;27-34.
39. Lechat P., Packer M., Chalon S., Cucherat M., Arab T., Boissel J.P. Clinical effects of beta-adrenergic blockade in chronic heart failure a meta-analysis of double-blind, placebo-controlled, randomized trials . Circulation. 98:1998;1184-1191.
40. Cleland J.G., McGowan J., Clark A., Freemantle N. The evidence for beta blockers in heart failure. BMJ. 318:1999;824-825.
41. Teerlink JR, Jalaluddin M, Anderson S, Kukin ML, Eichhorn E, Francis G, Packer M, Massie BM, on behalf of the PROMISE Investigators. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death: results from the PROMISE Study. Circulation 1999:in press.
42. Eichhorn E.J., Bristow M.R. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol. 79:1997;794-798.